Virijevic, Marijana (36969618100)Marijana (36969618100)VirijevicKraguljac-Kurtovic, N. (37037758700)N. (37037758700)Kraguljac-KurtovicPantic, N. (57221630977)N. (57221630977)PanticKnezevic, V. (56806620700)V. (56806620700)KnezevicMitrovic, M. (54972086700)M. (54972086700)Mitrovic2025-06-122025-06-122022https://www.scopus.com/inward/record.uri?eid=2-s2.0-85158084403&partnerID=40&md5=17b385cd2633b2b3edde3d712d46e6adhttps://remedy.med.bg.ac.rs/handle/123456789/3711Background: The minimal residual disease (MRD) level in patients with B-precursor acute lymphoblastic leukemia (B-ALL) is the strongest independent predictor of relapse and survival. Assessment of MRD plays a crucial role in the treatment of B-ALL. Case report: We performed long-term monitoring of a 30-year-old woman with B-ALL of standard risk for MRD using multiparametric flow cytometry (MFC). After five years of monitoring, molecular relapse of the disease was confirmed. Conclusion: This case illustrates that more extended monitoring for MRD, even by only MFC when other newer so-phisticated diagnostics are not available, is essential in detecting early relapse in patients with B-ALL of standard risk. © 2022, Lithografia Antoniadis I - Psarras Th G.P.. All rights reserved.B-precursor acute lymphoblastic leukemialate relapseMinimal residual diseasemultiparametric flow cytometry